Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00004049 | SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors | PHASE1 | COMPLETED | 36 | — | — | Apr 1, 1999 | - | Aug 29, 2018 | 1 | United States |
| NCT00003822 | SR-45023A in Treating Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 30 | — | — | Aug 1, 1998 | - | Aug 29, 2018 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| apomine | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists (surgery, radiotherapy, and/or chemotherapy) Measurable or evaluable disease by medical photograph, plain x-ray, CT, M...